Skip to content

Effects of subanesthetic dose of Esketamine on Acute Postoperative Pain and Postoperative Rehabilitation in Patients Undergoing Hip Replacement Surgery

Effects of subanesthetic dose of Esketamine on Acute Postoperative Pain and Postoperative Rehabilitation in Patients Undergoing Hip Replacement Surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600116506
Enrollment
Unknown
Registered
2026-01-12
Start date
2026-01-15
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Postoperative Pain and Postoperative Rehabilitation

Interventions

Experimental group:Administer 0.25 mg/kg of esketamine 5 minutes before skin incision, and continuously infuse it at a rate of 0.25 mg/kg/h during the operation until skin suture.
Control group:Administer an equivalent dose of normal saline 5 minutes before skin incision, and continuously infuse the same dose of normal saline during the operation.

Sponsors

General Hospital of the Eastern Theatre of the Chinese People's Liberation Army
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1) American Society of Anesthesiologists (ASA) physical status classification of I - III 2) Age ranging from 18 to 85 years old 3) Scheduled for hip replacement surgery under general anesthesia 4) Signed the informed consent form

Exclusion criteria

Exclusion criteria: 1) Refusal to participate 2) Known allergy or hypersensitivity to the study drug (esketamine) 3) Contraindications to esketamine, such as poorly controlled hypertension over a long period, unstable ischemic heart disease, increased intracranial pressure or intraocular pressure, etc. 4) Severe hepatic dysfunction (Child - Pugh class C and D) 5) Renal failure (requiring renal replacement therapy) 6) Daily use of benzodiazepines or opioids within 1 month or intermittent use within 3 months 7) History of drug or alcohol abuse 8) Language and cognitive impairment 9) Body Mass Index (BMI) >= 30 kg/m² or <= 15 kg/m²

Design outcomes

Primary

MeasureTime frame
The consumption of hydromorphone (converted to morphine milligram equivalent, MMSE);

Secondary

MeasureTime frame
Resting and movement pain scores (Numeric Rating Scale, NRS);Quality of Recovery - 15 (QoR - 15) score;Quality of Recovery - 15 (QoR - 15) score;Score of the Hip Joint System Function (Harris);Score of the Athens Insomnia Scale (AIS);Intraoperative hemodynamics;The satisfaction levels of anesthesiologists ;The consumption of drugs during the operation;The first pressing time of PICA;Incidence of postoperative adverse reactions;The time of tracheal tube extubation;Time to get out of bed;Discharge time;The number of presses of PCIA;The satisfaction of surgeons;The satisfaction of patients;

Countries

China

Contacts

Public ContactLidong Zhang

General Hospital of the Eastern Theatre of the Chinese People's Liberation Army

17796557161@163.com+86 138 1383 0315

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026